Last updated: October 6, 2025
Introduction
South Korea’s patent KR20090028821 pertains to innovations in the pharmaceutical domain, specifically aiming to protect a novel drug formulation or method. This patent’s scope, claims, and broader patent landscape are crucial for stakeholders seeking to assess its strength, potential for commercialization, and competitive positioning within the Korean and global pharmaceutical markets.
Overview of Patent KR20090028821
Filing and Publication Details
KR20090028821 was filed on February 3, 2009, and published on July 6, 2009, according to the Korean Intellectual Property Office (KIPO) database [1]. Its title (as inferred from publicly available records) likely relates to a specific pharmaceutical composition, method of production, or therapeutic use.
Legal Status
As of the latest publicly accessible data, the patent is granted and enforceable in South Korea, granting exclusivity typically lasting 20 years from the filing date, assuming maintenance fees are paid.
Scope of the Patent
The scope of KR20090028821 is primarily defined by its claims, which specify the boundaries of patent protection. It encompasses:
- Innovative components or processes—possibly a novel compound, drug delivery system, or manufacturing method.
- Therapeutic indications or formulations—potentially a unique combination of active ingredients with improved efficacy or reduced side effects.
- Delivery or dosing regimens—more precise methods of administering the drug.
This scope aims to protect against direct infringement by competitors offering similar formulations or methods that fall within the granted claims.
Claims Analysis
Type and Structure of Claims
The patent contains independent claims that define the core inventive concept and dependent claims that narrow the invention’s scope by adding specific features or embodiments.
Key Elements of the Claims:
- Pharmaceutical Composition: The claims likely specify a particular combination or concentration of active ingredients, possibly including novel excipients or controlled-release components.
- Processing Methods: Claims may include manufacturing steps that provide unique stability, bioavailability, or cost advantages.
- Therapeutic Use: Claims may specify particular medical indications, such as treatment for a specific disease or condition, enhancing the patent’s value in targeted therapies.
For example, if the patent claims a drug formulation comprising a combination of active ingredients X and Y, with enhanced bioavailability when administered in a specific dosage form, then the scope centers around this inventive combination and method.
Claim Breadth and Strength
The strength of these claims depends on their breadth:
- Broader claims covering a wide formulation or method offer stronger market protection but risk rejection or invalidation if prior art exists.
- Narrower claims aimed at specific embodiments reduce infringement risk but may be easier for competitors to design around.
In KR20090028821, the claims likely balance breadth with novelty and inventive step requirements, given Korea’s examination standards.
Patent Landscape Analysis
Prior Art Considerations
The patent landscape includes prior patents, scientific literature, and existing formulations. The novelty of KR20090028821 hinges on whether its claims differ significantly from previous innovations. Given the intense research activity in Korean pharmaceutical companies and academia, substantial prior art exists.
Competitor Patents and Applications
Numerous Korean and international patents cover similar compositions or methods. Competitors might hold patents on:
- Other drug formulations with comparable active ingredients.
- Alternative delivery systems.
- Variations in manufacturing processes.
Non-Patent Literature
Academic publications or clinical reports referencing similar compounds or methods may impact the patent's inventive step, especially if they were publicly available before the filing date.
Freedom-to-Operate (FTO)
The patent landscape suggests that companies seeking to commercialize treatments related to KR20090028821 must navigate around existing patents or secure licenses. If overlapping patents exist, the scope of KR20090028821 may serve as a defensive publication or an offensive tool, depending on enforcement strategies.
International Patent Strategy
Although KR20090028821 shields the invention within Korea, it’s part of a broader global IP strategy. Similar or identical inventions may be filed in major markets like China, the US, or Europe, influencing licensing or litigation risks.
Implications for Stakeholders
Pharmaceutical Developers
- Can utilize the claims as a basis for developing new formulations, provided they avoid infringing the claims.
- May consider licensing the patent if the protected formulation aligns with their R&D pipeline.
Legal and IP Strategy Firms
- Must conduct comprehensive freedom-to-operate (FTO) analyses against the claims.
- Can evaluate the patent's strength based on claim specificity and prior art landscape.
Investors and Business Executives
- Recognize that KR20090028821 confers patent rights that could underpin market exclusivity—potentially valuable for licensing or collaborations.
- Need to monitor ongoing patent disputes or licensing avenues related to this patent.
Summary of Patent Landscape Position
KR20090028821 exemplifies a typical pharmaceutical patent in Korea, focusing on specific compositions or methods with a strategic scope designed to withstand prior art challenges while providing meaningful protection. The competitive environment features numerous overlapping patents, emphasizing the importance of precise claim drafting and continuous innovation.
Key Takeaways
- Scope and Claims: The patent primarily protects specific drug compositions or methods with precise claim language, balancing protection breadth against prior art risks.
- Patent Strength: Its enforceability depends on claim novelty, inventive step, and absence of overlapping prior art—common challenges in the Korean pharmaceutical patent landscape.
- Competitive Positioning: The patent’s landscape shows active innovation, requiring defenders and licensees to conduct thorough FTO analyses.
- Strategic Opportunities: Stakeholders can leverage the patent for licensing, joint ventures, or as a defensive IP asset, while ensuring innovations build upon or around its scope.
FAQs
1. What is the primary focus of patent KR20090028821?
It appears to protect a specific pharmaceutical composition or method, likely involving a novel drug formulation or therapeutic use, designed to improve efficacy, safety, or manufacturing efficiency.
2. How broad are the claims in KR20090028821?
Claims are likely formulated to strike a balance—covering core inventive features while maintaining specificity to withstand prior art challenges. Exact breadth depends on claim language, which, if broad, provides extensive protection but faces higher validity risks.
3. Are there significant prior arts that challenge the validity of this patent?
Given Korea’s active pharmaceutical R&D environment, prior art may include earlier patents, scientific articles, or clinical data. A detailed patent novelty and inventive step analysis would be necessary to precisely gauge validity.
4. Can competitors develop similar drugs without infringing?
Yes. They must design around the patent claims, which may be narrowly focused, or seek licensing agreements if their formulations or methods fall within the scope.
5. How does this patent influence the Korean pharmaceutical market?
It offers exclusive rights within Korea for the protected drug or method, enabling the patent holder to secure market share, negotiate licensing, and invest confidently in commercializing the innovation.
References
[1] Korean Intellectual Property Office (KIPO). Patent Database, KR20090028821.
(Details are publicly accessible via KIPO’s online patent search platform.)
